Evidence map›Paper›PMID 23229687›Full record

ReviewClinical drug investigation2013

Pulmonary hypertension: use of oral drugs in patients with renal insufficiency.

Sarah Zimner-Rapuch, Sabine Amet, Nicolas Janus, Gilbert Deray, Vincent Launay-Vacher

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical drug investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah Zimner-RapuchService ICAR, Service de Néphrologie, Groupe Hospitalier Pitié-Salpétrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France. sarah.rapuch@psl.aphp.fr
Sabine Amet
Nicolas Janus
Gilbert Deray
Vincent Launay-Vacher
Pitié-Salpêtrière Hospital · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a progressive, fatal pulmonary circulatory disease that is characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PH has been reported to be highly prevalent in patients with chronic kidney disease, and especially among end-stage renal disease patients undergoing haemodialysis. However, only few data are available on drug dosage adjustment to renal function for those drugs that are commonly used in the treatment of PH. We reviewed the literature and gathered information, although sparse, to propose guidelines for using these drugs in renal insufficiency patients.

Indexed as

Administration, OralAntihypertensive AgentsBlood PressureDrug Dosage CalculationsHumansHypertension, PulmonaryKidneyRenal InsufficiencyTreatment OutcomeAntihypertensive Agents

Identifiers

PMID23229687
OpenAlexW2114683291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.